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PQUARTERLY FOCUS ISSUE: HEART FAILURE
Oscillatory Breathing and Exercise
Gas Exchange Abnormalities Prognosticate
Early Mortality and Morbidity in Heart Failure
Xing-Guo Sun, MD,* James E. Hansen, MD,* John F. Beshai, MD,†
Karlman Wasserman, MD, PHD*
Torrance, California; and Chicago, Illinois
Objectives The goal of this study was to identify better predictors of early death in patients with chronic left ventricular
heart failure (CHF). Potential predictors, derived from cardiopulmonary exercise testing, were compared with
other commonly used cardiovascular measurements.
Background The prediction of early death in patients with CHF remains challenging.
Methods Five hundred eight patients with CHF due to systolic dysfunction underwent resting cardiovascular measure-
ments, 6-min walking tests, and cardiopulmonary exercise testing. The peak oxygen uptake (V˙O2), peak oxygen
pulse, anaerobic threshold, ratio of ventilation to carbon dioxide output (V˙E/V˙CO2), slope of V˙E versus V˙CO2, and
presence or absence of a distinctive oscillatory breathing pattern (OB) were ascertained. Outcomes were
6-month mortality and morbidity, the latter a sum of cardiac hospitalizations and deaths.
Results The single best predictor of mortality was an elevated lowest V˙E/V˙CO2 (155% predicted). Adding OB on the ba-
sis of stepwise regression (optimal 2-predictor model), the odds ratio for mortality increased from 9.4 to 38.9
(p  0.001). The slope of V˙E versus V˙CO2 slope, peak V˙O2, peak oxygen pulse, and anaerobic threshold combined
with OB were also strong predictors. OB also increased the odds ratio 2- to 3-fold for each of these (p  0.01).
Kaplan-Meier survival curves and area under the receiver-operating characteristic curve confirmed that lowest
V˙E/V˙CO2 and OB were superior. For morbidity, elevated lowest V˙E/V˙CO2 or lower peak V˙O2 with OB were the best
predictors. No nonexercise measurements discriminated mortality and morbidity.
Conclusions Cardiopulmonary exercise testing parameters are powerful prognosticators of early mortality and morbidity in
patients with CHF, especially the optimal 2-predictor model of a combination of elevated lowest V˙E/V˙CO2 and OB.
(J Am Coll Cardiol 2010;55:1814–23) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.0752
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ehe incidence of chronic left ventricular heart failure
CHF) remains high despite improvements in its manage-
ent (1,2). Annual mortality rates as high as 20% to 30%
ave been reported during the past decade (3–6). The
election of accurate predictors of early death in patients
ith CHF remains challenging. Three reasonable ap-
roaches are to: 1) further refine well-known predictors;
rom the *Department of Medicine, Los Angeles Biomedical Research Institute at
arbor-UCLA Medical Center, Torrance, California; and the †Department of
edicine, University of Chicago Medical Center, Chicago, Illinois. The 3 investi-
ators from Harbor-UCLA Medical Center served as the core laboratory for analysis
f the exercise physiology of left ventricular heart failure due to systolic dysfunction
sed in 2 St. Jude Medical (St. Paul, Minnesota) clinical trials (Resynchronization for
emodynamic Treatment for Heart Failure Management and Cardiac Resynchro-
ization Therapy in Patients With Heart Failure and Narrow QRS Complexes). All
uthors received funding from St. Jude Medical. However, this study does not have
ny direct financial support from St. Jude Medical.h
Manuscript received August 6, 2009; revised manuscript received October 19,
009, accepted October 20, 2009.) evaluate new and more sensitive prognostic indicators;
nd 3) combine predictors.
See page 1824
Many reports have noted that gas exchange parameters
licited from cardiopulmonary exercise testing (CPX) help
uantify severity and predict survival in patients with CHF
7–14). These parameters are peak oxygen uptake (V˙O2, l/min
t 0°C, 760 mm Hg, dry), peak oxygen pulse (i.e., V˙O2/heart
ate), V˙O2 at anaerobic threshold (AT), and measures of
entilatory efficiency, that is, the relationship of minute venti-
ation (V˙E, l/min at body temperature, ambient atmospheric
ressure, saturated with water vapor) to carbon dioxide output
V˙CO2, l/min at 0°C, 760 mm Hg, dry) expressed as a ratio
V˙E/V˙CO2) or as the slope of V˙E versus V˙CO2. Ventilatory
fficiency measures, reflecting ventilation-perfusion mismatch,
ave been shown to predict death better than peak V˙O2 in
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April 27, 2010:1814–23 CPX Prognosticates CHF Death and Hospitalizationatients with CHF (14–22). Recent studies have shown that
scillatory breathing pattern (OB) during CPX in patients
ith CHF also predicts premature death (23–27).
hether survival is worse in those patients who stop
xercise because of dyspnea is disputed (28 –32).
As the CPX core laboratory for 2 St. Jude Medical (St. Paul,
innesota) multicenter studies, we analyzed the baseline CPX
nd 6-month survival and cardiac hospitalizations of 508
atients with CHF. We also compared these CPX parameters
lus OB with 6-min walk distance, resting and exercise heart
ate, systemic arterial systolic and diastolic blood pressure, left
entricular ejection fraction, quality of life, and New York
eart Association functional classification.
ethods
atients. The studies were sponsored and financed by St. Jude
edical using CPX protocols designed by us. Our role as the
PX core laboratory had Harbor-UCLA Institutional Re-
iew Board approval. In this study, we evaluated the
aseline studies of 508 patients with systolic dysfunction left
entricular failure who participated in 2 St. Jude Medical
iventricular pacing (BVP) and cardiac resynchronization
acing trials: RHYTHM (Resynchronization for Hemody-
amic Treatment for Heart Failure Management) (33) and
ethinQ (Cardiac Resynchronization Therapy in Patients
ith Heart Failure and Narrow QRS Complexes) (34).
ach patient, selected by a cardiologist or electrophysiolo-
ist at each site, received a biventricular implantable
ardioverter-defibrillator. Informed consent was obtained at
ach site. Each patient’s drug therapy was optimized before
is or her entry into the study. The core laboratory inves-
igators were blinded to patient assignments and imaging
esults at the time of data analysis but were aware of each
atient’s age, sex, height, weight, and New York Heart
ssociation functional class.
uality control, protocol, and systems. Prior to patient
esting, each site had to demonstrate that it could follow the
xercise protocol satisfactorily for 2 consecutive tests on a
ormal subject with good reproducibility in peak V˙O2, AT,
eak oxygen pulse, and lowest V˙E/V˙CO2 ratio. Our core lab
eviewed the tabular and graphical data (see the next
aragraph) from each study for evident breaches in protocol
nd calibration. Sites that failed to qualify were disqualified
rom study participation. Six different exercise systems were
sed at 69 sites. The mean  SD values between qualified
eplicate tests for the 69 sites were 5.1  4.1%, 5.2  5.1%,
.0  5.6%, and 4.0  3.0% for the 4 parameters,
espectively. As previously described (33), we, St. Jude
edical, and personnel at each site took care to minimize
ailures by oversight, training, and proven reproducibility
efore CPX was performed on patients. If we questioned
esults, the relevant site lab had to prove its validity by
equalification and repeat patient testing. The baseline CPX
tudies were done within 2 weeks of device implantation.
he exercise protocol required measurements during 3 min lf rest, 3 min of unloaded cycling,
r comparable warm-up on the
readmill, followed by a progres-
ively increasing work rate of 5 to
5 W/min (usually 10 W/min) in
ramp pattern or 1-min step in-
ervals to maximal tolerance. Fifty-
ight percent of studies were per-
ormed on the cycle ergometer.
ork rate increases were individ-
ally selected so that subjects
ould reach their maximal toler-
ted work rate in 6 to 15 min of
xercise, whether on the cycle or
readmill (33–35). After recovery,
he patient was asked to report the
eason(s) for stopping. Peak V˙O2,
eak oxygen pulse, and AT values
rom treadmill exercise were re-
uced by 11%, to be comparable
ith cycle values (35). Ventilatory
fficiency and heart rate values
ere not adjusted.
ata analysis, display, and gas
xchange measurements. To
inimize the interobserver and
ystem variability, all systems
ere used only to collect the raw breath-by-breath CPX
ata, which were transmitted to the core laboratory for
nalyses. The following method of data analysis was used
33). Breath-by-breath CPX data were interpolated second
y second and sequentially averaged in 10-s bins. To best
nalyze the physiological responses, data were placed into
niform tabular formats, and optimally scaled 15 exercise
ariables were displayed in 9-panel graphs (Fig. 1) (33,35,36).
Peak V˙O2 was determined as the highest average value
uring a sequential 30-s period (Fig. 1C). Peak heart rate
nd peak oxygen pulse were determined as concurrent 30-s
verages (Fig. 1B). The AT was measured by the V-slope
ethod (37) using 10-s averages (Fig. 1E). The lowest
˙ E/V˙CO2 was the lowest average 90-s value during exercise
38,39) (Fig. 1F). The slope of V˙E versus V˙CO2 and
ntercept (Fig. 1D) were determined by linear regression
elow the ventilatory compensation point (Fig. 1D)
16,38,39).
Percents of predicted values (%pred) for peak V˙O2, peak
xygen pulse, and AT values depend on age, size, sex, and
orm of ergometry (33,35,36,39). The %pred of the lowest
˙ E/V˙CO2 and slope of V˙E versus V˙CO2 values depend on age,
ex, and size (38).
B. OB was defined as 3 or more consecutive cyclic
uctuations of ventilation during CPX. To be defined as
ositive, the amplitude of oscillatory ventilation must exceed
0% of concurrent mean ventilation with a complete oscil-
Abbreviations
and Acronyms
AT  anaerobic threshold
AUC  area under the
receiver-operating
characteristic curve
BVP  biventricular pacing
CHF  chronic heart failure
CPX  cardiopulmonary
exercise testing
CRT  cardiac
resynchronization therapy
OB  oscillatory breathing
pattern
OR  odds ratio
%pred  percent of
predicted value
V˙CO2  carbon dioxide
output per minute (0°C,
760 mm Hg, dry)
V˙E  minute ventilation
(body temperature, ambient
atmospheric pressure,
saturated with water vapor)
V˙O2  oxygen uptake per
minute (0°C, 760 mm Hg, dry)atory cycle within 40 to 140 s. Oscillations of similar
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CPX Prognosticates CHF Death and Hospitalization April 27, 2010:1814–23requency must also be visible in 3 or more of the following
ariables: oxygen pulse, V˙O2, V˙CO2, V˙E/V˙CO2, respiratory
xchange ratio (i.e., V˙CO2/V˙O2), or end-tidal pressures for
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Figure 1 9-Panel Display of CPX Data in an OB Patient With CH
There are clear oscillatory patterns of minute ventilation (V˙E) (A), oxygen pulse (B)
V˙E/V˙O2 and V˙E/V˙CO2 (F), respiratory exchange ratio (RER) (H), and end-tidal PO2 (PE
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vertical dashed line), and recovery (right of right vertical dashed line) for V˙E (A); h
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x-axis) (E) (37); ventilatory equivalents for oxygen (V˙E/V˙O2) and carbon dioxide (V˙E/
V˙E/V˙CO2 ratio during exercise (38) (F); tidal volume (VT) versus V˙E with inspiratory
maximal voluntary ventilation (MVV) intersecting on the x-axis (G); RER (H); and PE
ventricular heart failure; CPX  cardiopulmonary exercise testing; OB  oscillatoryxygen and carbon dioxide (Fig. 1). cther data. At each site, resting and exercise heart rate,
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April 27, 2010:1814–23 CPX Prognosticates CHF Death and Hospitalizationraction, echocardiographic (interpreted by the echocardi-
graphy core laboratories), and quality-of-life data were
easured. The latter used the Minnesota Living With
eart Failure Questionnaire, with scores ranging from 0 to
05, with higher scores indicating poorer quality of life (34).
hese baseline measurements and 6-month outcomes were
valuated only after completing our CPX analyses. The
ortality outcome was all-cause death; the morbidity out-
ome included death or a cardiac hospitalization for 24 h or
ore.
tatistical analysis. Data, expressed as mean  SD unless
pecially noted, were first analyzed using unpaired t and chi-
quare tests. New York Heart Association functional classes were
nalyzed using the Mann-WhitneyU test (40). A 2-tailed p value
0.05 was considered significant. Using all-cause mortality or
orbidity at 6 months as outcome, receiver-operating character-
stic curve analyses were performed. To detect an optimal cutoff
alue, we computed and searched for the shortest distance on its
eceiver-operating characteristic curve, that is, distance 
1  sensitivity2 1  specificity2 (41) by changing
evels as follows: 2 decimals for absolute values, whole numbers
or weight-normalized values, and 5% for %pred. On the basis
f the optimal cutoff value, sensitivity, specificity, and area
nder the receiver-operating characteristic curve (AUC) were
eported. Using the optimal cutoff value, univariate and mul-
ivariate regression analyses were performed to obtain the
ptimal predictor model and to evaluate prognostic values
42,43). To evaluate the effect of adding OB on the key CPX
easures, we used step-by-step repeated multivariate analyses
o obtain the next model by excluding the most significant
ariables of prior analysis. Odds ratios (ORs) were calculated
nd tested using a Wald logistic regression model and are
resented for important single and combined predictors. The
R of the combined 2-predictor model compared these of 2
emographics, Clinical Characteristics, and Resting Measurementf Between Positive nd Negative Mortality, Morbidity, nd OB SubTable 1 Demographics, Clinical Characteristics, and Resting Mof Between Positive and Negative Mortality, Morbidity
Variable
All Patients
(n  508)
Mortality
(n  489)
Morta
(n  1
Men 355 (70%) 340 (70%) 15 (79
Age (yrs) 64 12 64 12 66 1
Height (cm) 172 10 172 10 171 7
Weight (kg) 87 22 88 22 76 1
Resting HR (beats/min) 77 14 76 13 86 2
Resting SBP (mm Hg) 118 19 118 19 115 2
Resting DBP (mm Hg) 71 11 71 11 71 9
NYHA functional class
II/III/IV
52/440/16 52/423/14 0/17/
LVEF (%) 26 7 26 7 22 6
QRS interval (ms) 138 33 138 33 142 2
QRS interval 120 ms 284 (56%) 271 (55%) 13 (68%
Quality of life (score) 51 25 51 26 53 2
6-min walk distance (m) 291 101 293 100 239 1
BVP/CRT on 363 (71%) 348 (71%) 15 (79%
ata are expressed as n (%) or mean  SD. *p  0.05, †p  0.01, and ‡p  0.001, positive gro
BVP biventricular pacing; CHF chronic left ventricular heart failure; CRT cardiac resynchronization
YHA  New York Heart Association; OB  oscillatory breathing pattern; SBP  systolic blood pressure.easurements both abnormal with these of 2 measurements
oth normal. Kaplan-Meier survival curves were constructed,
nd log-rank tests were performed to compare the most
mportant single and combined predictors. Statistical software
sed were SPSS version 15.0 (SPSS, Inc., Chicago, Illinois),
rigin version 7 (OriginLab Corporation, Northampton,
assachusetts), and SigmaPlot version 8.0 (Aspire Software
nternational, Ashburn, Virginia). Graphs were generated
sing Origin or SigmaPlot.
esults
esting and preliminary data. Patient demographics and
esting measurements are shown in Table 1. During
-month follow-up, 19 patients died and 489 patients
urvived, with a total mortality rate of 3.7%. One hundred
even patients had 1 or more cardiac hospitalizations lasting
24 h or death, with a total morbidity rate of 21%. Two
undred fifty-eight patients with CHF (51%) were identi-
ed as OB positive. Approximately three-quarters of pa-
ients were men; the mean age, height, and weight were 64
ears, 172 cm, and 87 kg, respectively. Survivors were
eavier (p  0.001), but sex, age, and height were not
ignificantly different (p  0.05). Resting heart rate and
ystemic arterial systolic and diastolic blood pressure did not
iffer (p  0.05). Most patients were in New York Heart
ssociation functional class III (n  440 [87%]), with 52
10%) in class II and 16 (3%) in class IV. Survivors’ New
ork Heart Association functional classifications were less
evere than those of nonsurvivors (p 0.031). Survivors’ left
entricular ejection fractions were significantly higher than
hose of nonsurvivors (26  7% vs. 22  6%, p  0.023).
either QRS interval duration nor quality-of-life scores
iffered significantly (p  0.85 and p  0.67, respectively).
Their Comparisonsps in Patients With CHFrements and Their Comparisons
OB Subgroups in Patients With CHF
Morbidity
(n  401)
Morbidity
(n  107)
OB
(n  258)
OB
(n  250)
278 (69%) 77 (72%) 183 (70%) 172 (67%)
64 12 64 14 63 12 64 13
172 10 171 7 173 10 171 10*
88 22 83 21 89 22 85 21*
76 13 80 17* 76 14 78 14
118 19 116 21 119 19 117 19
71 11 71 11 72 11 70 11
47/345/9 5/95/7* 21/228/9 31/212/7
26 7 25 7 27 7 25 7‡
138 33 138 32 137 33 140 32
265 (69%) 71 (72%) 132 (51%) 152 (61%)*
50 26 55 22* 48 24 54 27*
300 99 264 104† 312 94 270 103‡
283 (70%) 80 (74%) 182 (72%) 181 (71%)
sus negative groups using chi-square test, unpaired t test, or U test.s andgroue s
, and
lity
9)
%)*
4
1‡
2
1
2*
*
5
)†
3
06
)
ups ver
therapy; DBP diastolic blood pressure; HR heart rate; LVEF left ventricular ejection fraction;
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CPX Prognosticates CHF Death and Hospitalization April 27, 2010:1814–23he 6-minute walk distance was borderline lower in non-
urvivors (239  106 m vs. 293  100 m, p  0.056).
either the presence nor the absence of cardiac resynchro-
ization therapy (CRT) settings influenced 6-month sur-
ival. The trends in morbidity were similar to those in
ortality (Table 1). However, the presence of OB increased
he likelihood and statistical significance of poorer left
entricular ejection fraction, quality of life, and 6-min walk
istance.
There were 210 on and 61 off for the BVP and CRT
ettings of RHYTHM patients (QRS interval 150 ms).
HF Population Deaths andospitalizations in 6 MonthsTable 2 CHF Population Deaths andHospitalizations in 6 Months
Study BVP/CRT Death
Cardiac
Hospitalization
(Including Death)
RethinQ (n  237)* On (n  152)* 5 (3.3%) 31 (20.4%)
Off (n  85) 2 (2.3%) 17 (20.0%)
RHYTHM (n  271)† On (n  210) 9 (4.3%) 48 (23.0%)
Off (n  61) 3 (4.9%) 11 (17.7%)
Includes patients in registry group for BVP or CRT on (34). †Includes all patients with baseline
ardiopulmonary exercise testing but excludes data of crossover patients (33).
RethinQ  Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS
omplexes; RHYTHM Resynchronization for Hemodynamic Treatment for Heart Failure Manage-
ent; other abbreviations as in Table 1.
PX Measurements and Their Comparisons of Between Negative aortality, Morbidi y, and OB Subgroup i Patien s With CHFTable 3 CPX Me surements and Their C mparisons of BetweeMortality, Morbidity, and OB Subgroups in Patients Wi
Measurement
All Patients
(n  508)
Mortality
(n  489)
Morta
(n  1
Dyspnea-limited exercise 194 (37%) 187 (38%) 7 (36%
Peak HR (beats/min) 108 21 108 20 109 27
Peak SBP (mm Hg) 141 26 142 26 132 24
Peak DBP (mm Hg) 77 14 77 14 74 10
Peak V˙E (l/min) 43 15 43 15 37 10
Peak work load (W) 60 37 61 37 39 29
Peak RER (ratio) 1.07 0.13 1.07 0.13 1.01 0.
Peak V˙O2
%pred 53 16 53 16 40 14
ml/min/kg 12.1 4.0 12.2 4.0 9.6 3.
l/min 1.00 0.40 1.01 0.40 0.72 0.
AT (n  491)
%pred 57 16 57 16 47 13
ml/min/kg 8.8 2.5 9.1 2.6 8.0 2.
l/min 0.72 0.26 0.73 0.26 0.57 0.
Peak oxygen pulse
%pred 77 23 78 23 58 20
ml/beat 9.4 3.6 9.5 3.6 6.6 2.
Lowest V˙E/V˙CO2 ratio
%pred 137 34 135 33 173 40
Ratio 39.2 10.2 38.8 10.1 50.1 12
Slope of V˙E versus V˙CO2
%pred 120 59 119 59 161 46
Slope 35.3 17.1 34.9 17.0 46.9 14
Intercept 3.0 3.3 3.1 3.3 2.3 3.
ata are expressed as mean  SD. *p  0.05, †p  0.01, ‡p  0.001, and §p  0.0001, positi
AT anaerobic threshold; oxygen pulse V˙O2/HR; %pred percent of predicted value; RER r
˙ioxide output per min (0°C, 760 mm Hg, dry); VE minute ventilation (body temperature, ambient atmo
er minute (0°C, 760 mm Hg, dry); other abbreviations as in Table 1.here were 152 on (including 67 nonrandomized patients in
he registry group) and 85 off for the BVP and CRT settings
f RethinQ patients (QRS interval 130 ms). There were
o differences in mortality and morbidity between differing
tudy groups (Table 2). All patients were reported to be on
table medical regimens for CHF treatment. All received
ngiotensin-converting enzyme inhibitors (82%) or angio-
ensin receptor blockers (18%); 86% received beta-
drenergic blockers.
PX measurements. All patients performed baseline CPX
afely and without complications: 58% used the cycle and
2% used the treadmill. Seventeen patients (3%) completed
heir exercise before the end of 3-min warm-up; the
emaining 491 (97%) exercised longer. Exercise duration,
ncluding warm-up, was 8.4  3.3 min. The AT was
ndeterminate in 17 patients (15 survivors and 2 nonsurvi-
ors and 3 OB negative and 14 OB positive). One hundred
inety-five patients (38%) stated they were predominantly
imited by dyspnea, 289 (56%) by fatigue, and 24 (5%) by
ther factors. The limiting symptom was not significantly
elated to early death at 6 months (OR: 0.99; 95% confi-
ence interval: 0.01 to 1.97).
Table 3 compares mortality, morbidity, and OB for each
PX parameter. Exercise capacity decreased in all patients,
sitiveative and Positive
F
Morbidity
(n  401)
Morbidity
(n  107)
OB
(n  258)
OB
(n  250)
160 (33%) 34 (32%) 104 (40%) 90 (36%)
108 21 107 22 110 21 106 20*
142 26 137 25 145 25 137 25‡
77 14 76 13 78 13 76 14*
44 15 40 14* 45 15 40 14‡
63 38 51 31† 68 39 53 33‡
1.07 0.13 1.08 0.14 1.07 0.13 1.08 0.14
54 16 46 15§ 56 16 49 16§
12.4 4.1 10.7 3.4§ 13.1 4.1 11.0 3.7§
1.04 0.40 0.86 0.36§ 1.10 0.40 0.90 0.37§
59 16 51 13§ 60 15 54 16‡
9.0 2.6 8.0 2.2§ 9.4 2.6 8.2 2.3§
0.75 0.26 0.63 0.23§ 0.78 0.27 0.67 0.23§
79 23 68 22§ 81 22 73 23§
9.7 3.6 8.2 3.4§ 10.2 3.7 8.6 3.3§
133 34 149 34§ 129 25 145 40§
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April 27, 2010:1814–23 CPX Prognosticates CHF Death and Hospitalizationspecially in nonsurvivors and those hospitalized or with
B. Absolute and %pred values for peak V˙O2, AT, peak
xygen pulse, lowest V˙E/V˙CO2 ratio, and slope of V˙E versus
˙ CO2 were all significantly worse in nonsurvivors (p 
.05). Peak V˙E and peak work load were also lower in
onsurvivors (p  0.05). Peak exercise heart rate, systemic
rterial systolic and diastolic blood pressure, and respiratory
xchange ratio were not discriminatory (p  0.05). The
PX patterns for morbidity and OB were similar to those
or mortality, often with increasing statistical significance
Table 3).
Sensitivity and specificity analyses, cutoff values, and
UC analyses for single or combinations of parameters are
hown in Table 4. The order of most to least significance
as lowest V˙E/V˙CO2 ratio, slope of V˙E versus V˙CO2, peak
˙ O2, peak oxygen pulse, OB, AT, and 6-min walk distance
p  0.001 to p  0.05). With the best cutoff of
55%pred, the lowest V˙E/V˙CO2 ratio had the highest
UC of 0.748, which increased to 0.797 when combined
ith OB. The left ventricular ejection fraction, QRS
nterval duration, quality of life, and New York Heart
ssociation functional classification were not significant
redictors of nonsurvival.
OR mortality analyses, combining OB and gas exchange
arameters (Fig. 2A), were invariably consistent with the AUC
nalyses in Table 4. The combination of the lowest V˙E/V˙CO2
ensitivity, Specificity, AUC With 95% CI, and Best Cutoff Values fTable 4 Sensitivity, Specificity, AUC With 95% CI, and Best Cu
Measurement and
Best Cutoff Value
Single Meas
Sensitivity Specificity
Peak V˙O2
50%pred 0.79 0.59 0
11 ml/min/kg 0.74 0.60 0
0.80 l/min 0.68 0.65 0
AT (n  491)
60%pred 0.88 0.39 0
9 ml/min/kg 0.88 0.42 0
0.60 l/min 0.82 0.51 0
Peak oxygen pulse
75%pred 0.84 0.50 0
7.5 ml/beat 0.68 0.66 0
Lowest V˙E/V˙CO2 ratio
155%pred 0.68 0.78 0
Ratio 40 0.74 0.65 0
Slope of V˙E versus V˙CO2
140%pred 0.63 0.79 0
Slope 40 0.63 0.74 0
OB 0.84 0.49 0
Dyspnea-limited exercise 0.37 0.59 0
LVEF 25% 0.61 0.51 0
QRS interval 120 ms 0.68 0.43 0
BVP/CRT off 0.16 0.68 0
Quality-of-life score 50 0.61 0.42 0
6-min walk distance 250 m 0.61 0.68 0
NYHA functional class IV 0.11 0.94 0UC  area under the receiver-operating characteristic curve; CI  confidence interval; other abbreviatioatio with OB, the optimal 2-predictor model, yielded an OR
f 38.9 (Fig. 2A). Using best cutoff values, the ORs of %pred
alues were higher than those of the absolute values for the
owest V˙E/V˙CO2 ratio, slope of V˙E versus V˙CO2, peak V˙O2, peak
xygen pulse, and AT (Fig. 2A). The elevated lowest V˙E/V˙CO2
atio was also the best single predictor by both OR (Fig. 2A)
nd Kaplan-Meier plot analyses (Fig. 3A). Using stepwise
ultivariate regression analysis, the lowest V˙E/V˙CO2 ratio was
nvariably picked first, reducing all other CPX measurements
xcept OB to nonsignificance. There were significant increases
n OR for lowest V˙E/V˙CO2 ratio, slope of V˙E versus V˙CO2, peak
˙ O2, peak oxygen pulse, and AT, by combining OB. However,
here were no significant increases in OR by combining peak
˙ O2, peak oxygen pulse, or AT with lowest V˙E/V˙CO2 ratio.
orbidity OR analyses were significant for absolute and
ormalized values (Fig. 2B). The morbidity OR values were
ower than those of mortality; adding OB always increased the
R values.
Figure 3 shows the Kaplan-Meier curves for lowest
˙ E/V˙CO2 ratio (155%pred) and OB for mortality (Fig.
A) and morbidity (Fig. 3B). The 6-month survival rate was
7.6% in patients with elevated lowest V˙E/V˙CO2 ratio
155%pred), 93.8% in those with positive OB, and 84.6%
n those with both elevated lowest V˙E/V˙CO2 ratio
155%pred) and positive OB. For patients with more
ormal lowest V˙E/V˙CO2 ratio or negative OB or both, the
ortality in Patients With CHFalues for Mortality in Patients With CHF
nt Combined With OB
(95% CI) p Value AUC (95% CI) p Value
0.590–0.813) 0.003 0.760 (0.661–0.860) 0.001
0.532–0.771) 0.025 0.747 (0.646–0.848) 0.001
0.555–0.802) 0.008 0.744 (0.632–0.856) 0.001
0.549–0.772) 0.024 0.723 (0.616–0.829) 0.001
0.529–0.757) 0.047 0.712 (0.605–0.819) 0.002
0.512–0.779) 0.042 0.686 (0.579–0.794) 0.006
0.576–0.790) 0.007 0.751 (0.650–0.851) 0.001
0.575–0.789) 0.007 0.747 (0.660–0.834) 0.001
0.624–0.872) 0.001 0.797 (0.701–0.893) 0.001
0.589–0.823) 0.002 0.763 (0.665–0.862) 0.001
0.594–0.852) 0.001 0.774 (0.663–0.885) 0.001
0.572–0.829) 0.003 0.757 (0.646–0.868) 0.001
0.566–0.781) 0.009
0.361–0.625) 0.92
0.443–0.705) 0.71
0.438–0.692) 0.34
0.312–0.556) 0.33
0.401–0.662) 0.64
0.513–0.776) 0.033 0.728 (0.629–0.827) 0.001
0.402–0.675) 0.57or Mtoff V
ureme
AUC
.701 (
.652 (
.679 (
.661 (
.643 (
.645 (
.683 (
.682 (
.748 (
.706 (
.723 (
.700 (
.674 (
.493 (
.574 (
.565 (
.434 (
.532 (
.644 (
.538 (ns as in Tables 1 and 3.
s
9
a
(
6
7
e
O

w
D
O
C
C
r
f
[
o
t
2
t
o
d
(
p
A
m
w
i
m
t
f
O
b
s
i
p
e
1820 Sun et al. JACC Vol. 55, No. 17, 2010
CPX Prognosticates CHF Death and Hospitalization April 27, 2010:1814–23urvival rates were significantly higher (98.5%, 98.8%, and
9.5%, respectively) (Fig. 3A). Morbidity Kaplan-Meier
nalyses (Fig. 3B) were similar to those of mortality
Fig. 3A). The 6-month hospitalization-free rates were
4.6% for elevated lowest V˙E/V˙CO2 ratio (155%pred),
4.7% for positive OB, and 56.6% for patients with both
levated lowest V˙E/V˙CO2 ratio (155%pred) and positive
B, compared with 82.5% for lowest V˙E/V˙CO2 ratio
155%pred, 83.1% for negative OB, and 83.3% for patients
ith both V˙E/V˙CO2 ratio 155%pred and negative OB.
iscussion
B in CHF. OB has been linked to strokes and advanced
HF (23–27). The prevalence of OB in our patients with
HF approximates 50%, quite similar to that of other
eports (24–27). Prior standards for the recognition of OB
ocused on the magnitude of the oscillations (V˙E by 25%
25] or 30% [26,27]) and required 2 or more consecutive
scillations (24–26) or occurred over 60% of the exercise
0.5 1 2 5 10 20 30 40 50
  5.8 16.2
4.6  15.4
A
Odds Ratio
 Peak VO2         (<50%pred)
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                        (<0.80L/min)
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                     (<9mL/min/kg)
                        (<0.60L/min)
 Peak O2Pulse (<75%pred)
                       (<7.5mL/beat)
 Lowest VE/VCO2(>=155%p)
                                  (>=40)
 VE-VCO2 Slope (>=140%p)
                                   (>=40)
 Oscillatory Breathing
Prognosis for 6m mortality Combined
 Variables (cutoff) Alone with +OB
Lower Mortality                     Higher Mortality
  6.0 19.5
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  5.8 22.6
   7.6  19.7
     5.7  15.1
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Figure 2 OR of CPX Variables, Alone and Combined With Posit
(A) Mortality. The left column shows the optimal cutoff values for each variable w
for single measures alone; the red bars are ORs for the CPX measures combined
dictor model is a 2-predictor model of the lowest V˙E/V˙CO2 ratio (155% of predicte
all others become nonsignificant, p  0.05). All other 2-predictor models (1 of key
stepwise multivariate regression analysis, excluding the most significant CPX mea
for prognosis. All obtained models are always the 2-predictor model combining 1 o
key measures. When key CPX measures were combined with OB, the ORs were
combination with OB, the prognostic significance from high to low is %pred  per
(OR: 9.4), and the best combination is lowest V˙E/V˙CO2 ratio (155%pred) with O
data. Abbreviations as in Figure 1.ime (27). To be OB positive, we required that: 1) V˙E have wor more consecutive oscillations with amplitudes30% of
he mean; 2) 3 or more other gas exchange variables also
scillate at the same frequency; and 3) each oscillatory cycle
uration be between 40 and 140 s. In this and other reports
24–27), a close linkage between OB and clinical and
hysiological severity has been found.
bnormal exercise gas exchange and OB can predict
ortality and increasing morbidity. In our study, OB
as found to be an independent and good prognostic
ndicator not only of early death but also of increasing
orbidity in patients with CHF. Alone, it is not superior
o peak V˙O2 or slope of V˙E versus V˙CO2, as some have
ound (25–27). However, it is clear from this study that
B is a significant independent predictor and, in com-
ination with other abnormal CPX gas exchange mea-
urements, makes them even more important in predict-
ng both mortality and morbidity. It increases the
rognostic importance of all other abnormal CPX gas
xchange parameters. For clinical application of CPX, it
1 2 3 4 5
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ir mean odds ratios (ORs) and 95% confidence intervals. The blue bars are ORs
OB. All key CPX measures and OB alone have significant ORs. The optimal pre-
e [%pred]) with OB by stepwise multivariate regression analysis (p  0.001;
easures with OB) on the right side are obtained by the step-by-step repeated
at the last analysis, to evaluate the effect of adding OB on key CPX measures
ey CPX measures with OB. There is no predictor model using any 2 of the CPX
antly increased (p  0.05 to p  0.001). For each CPX measurement and the
m  absolute. The best single predictor is lowest V˙E/V˙CO2 ratio (155%pred)
38.9). (B) Morbidity. Although the ORs are lower, the trends confirm the mortality 
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April 27, 2010:1814–23 CPX Prognosticates CHF Death and Hospitalizationmportant factors for grading the severity of CHF. Therapy
hat decreases OB should be welcomed.
Many prior studies have demonstrated the importance of
xercise gas exchange parameters in evaluating patients with
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CPX Prognosticates CHF Death and Hospitalization April 27, 2010:1814–23ciency, presumably reflecting the degree of ventilation-
erfusion mismatch secondary to low cardiac output, was a
etter predictor of early death than peak V˙O2. More important,
n our study, the combination of a positive OB and lowest
˙ E/V˙CO2 ratio 155%pred or slope of V˙E versus V˙CO2
140%pred or AT 60%pred or peak V˙O2 50%pred or
eak oxygen pulse75%pred had 13 or more times higher risk
or death within 6 months than if these findings were not
resent. Adding OB increased the OR for single measure-
ents 2- to 4-fold. For all key CPX measurements, the %pred
utoff values were superior to absolute values, probably because
t lessens differences between sex, body size, and age. Adding
eak V˙O2, peak oxygen pulse, or AT did not add significant
rognostic importance to the lowest V˙E/V˙CO2 ratio, probably
ecause of the overlapping of their physiological information
nd high correlations with each other.
omparing prognosis using other measurements. Although
ome investigators have reported that dyspnea rather than
atigue as the symptom terminating exercise indicates a worse
rognosis in CHF (28–30), other reports and this study do not
onfirm this (31,32). We found by t test that higher body
eight, lower New York Heart Association functional classi-
cation, and higher left ventricular ejection fraction signifi-
antly improved survival (Table 1). But by AUC analysis using
est the cutoff (Table 4), they were not significant predictors
p  0.05). However, lower 6-min walk distance with OB
uring CPX worsened 6-month survival. No other single or
ombined measurements reached significance comparable with
he combination of OB and CPX gas exchange parameters.
tudy limitations. LOW DEATH RATE. A limitation of this
nalysis is the modest number of deaths (n  19) over the
-month follow-up period. However, the prognostic analysis
f morbidity (n  107) confirms the key findings for the
ortality analysis. Each key CPX parameter and OB are
ndependent indicators of mortality and morbidity. Combining
PX parameters with OB increases their prognostic impor-
ance. The risk for type I error may exist because of the large
umber of variables tested.
AMPLING BIAS. A potential selection bias may have occurred,
ecause the patients with CHF analyzed in this study were
nrolled in CRT clinical trials and thus not representative of
he whole spectrum of patients with CHF. These patients
ould have been protected by their devices, although we did not
nd a difference in survival between the CRT-off group and
RT-on group. In addition, this analysis included patients
ith normal QRS interval durations (120 ms) from the
ethinQ study, who do not meet current indications for CRT
34). The low overall 6-month death rate of 3.7% in the
atients with CHF with a mean age of 65 years may be due to
etter physician management, treatment improvements, and
ardioverter-defibrillator and/or pacemaker use. In general,
VP or CRT may improve synchronization in CHF
33,34,44), and that improvement might have been a potential
ontributor to the low death rate of this study.
kUALITY CONTROL AND STANDARD DATA ANALYSIS OF CPX
OR THE MULTICENTER STUDY. CPX gas exchange mea-
urements are dependent on the quality of the equipment, the
kills of technicians, and the calculation methods of software.
fter being qualified for the studies, if we questioned results on
patient’s test, the relevant site lab had to prove its validity by
equalification and repeat patient testing. This occurred 14
imes at 12 laboratories and required 36 additional full CPX
ests before we requalified the laboratories and accepted pa-
ients’ test results. Therefore, the bias resulting from system
rrors were minimized. Although there were 6 different sys-
ems and many different versions of software at the 69 sites, we
sed them only for raw data collection rather than data analysis
nd reporting. Only one standard method of data analysis and
eporting was used, so that the bias of interobserver and system
oftware variability was minimized.
Although we used both treadmills and stationary cycles,
ach patient was always exercised on the same ergometer. Prior
tudies (35) have indicated that treadmill increases peak V˙O2,
eak oxygen pulse, and AT by an average of 11% over cycle
alues but does not influence peak heart rate, peak V˙E, lowest
˙ E/V˙CO2 ratio, or slope of V˙E versus V˙CO2 (38).
onclusions
n this study, we found that the combination of OB and gas
xchange data collected during CPX are powerful indicators of
-month survival or death and morbidity of patients with
HF. For mortality, the lowest V˙E/V˙CO2 ratio, with cutoff of
55%pred, was the best single predictor, with an OR of 9.4 and
n AUC of 0.748. Adding OB increased the OR to 38.9 and
he AUC to 0.797. For future clinical trials and daily practice,
he lowest V˙E/V˙CO2 ratio and/or other parameters (e.g., peak
˙ O2, AT, peak oxygen pulse), when combined with OB,
rovide objective grading of heart failure severity. This might
e preferable to the subjective grading of heart failure severity,
s is commonly used in the recruitment of patients with CHF
nto clinical trials. It would have the advantage of obtaining
ore uniform patient responses. Finally, it needs to be recog-
ized that good quality control is essential for clinical trials,
articularly involving multiple centers.
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